According to the AML-BFM 2004 Interim (first period) protocol, all patients with FLT3-ITD were classified into the high-risk group and were intended to receive SCT from a matched sibling donor, or in cases of non-response, also from a matched unrelated donor. The gene discussed is FLT3; the disease is acute myeloid leukemia.